Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Silybin is metabolized by cytochrome P450 2C8 in vitro

P Jancova, E Anzenbacherova, B Papouskova, K Lemr, P Luzna, A Veinlichova, P Anzenbacher, V Simanek

. 2007 ; 35 (11) : 2035-2039.

Language English Country United States

Silybin (a flavonolignan, the main component of silymarin, an extract from the seeds of Silybum marianum) has been used to date mostly as a hepatoprotectant. However, it also has other interesting activities, e.g., anticancer and hypocholesterolemic effects. It is also known that silybin can inhibit the activities of the cytochrome P450 (P450) enzymes. In this study, a weak interaction of silybin with human microsomal CYP2E1, 2A6, 2B6, 2C19, and 2D6 (IC(50) > or = 250 microM) was found; a moderate inhibition was observed for CYP1A2 and 2C8. The most prominent inhibition effect was found with CYP3A4 and CYP2C9 (IC(50) < or = 50 microM). Using mass spectometry detection, production of O-demethylated (the main metabolite) as well as hydroxylated derivatives of silybin formed by P450 enzymes was detected. The effect of different P450 inhibitors on the formation of O-demethylated product was also studied. In particular, a relatively specific inhibitor of CYP2C8 (quercetin) markedly inhibited the formation of this metabolite. With the help of recombinant enzymes (bactosomes), it was confirmed that the CYP2C8 enzyme is responsible for the reaction leading to O-demethylated silybin.

000      
00000naa 2200000 a 4500
001      
bmc10026807
003      
CZ-PrNML
005      
20111210192459.0
008      
101019s2007 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jančová, Petra $7 xx0114108
245    10
$a Silybin is metabolized by cytochrome P450 2C8 in vitro / $c P Jancova, E Anzenbacherova, B Papouskova, K Lemr, P Luzna, A Veinlichova, P Anzenbacher, V Simanek
314    __
$a Faculty of Medicine, Department of Medical Chemistry and Biochemistry, Faculty of Sciences, Palacky University at Olomouc, Olomouc, Czech Republic.
520    9_
$a Silybin (a flavonolignan, the main component of silymarin, an extract from the seeds of Silybum marianum) has been used to date mostly as a hepatoprotectant. However, it also has other interesting activities, e.g., anticancer and hypocholesterolemic effects. It is also known that silybin can inhibit the activities of the cytochrome P450 (P450) enzymes. In this study, a weak interaction of silybin with human microsomal CYP2E1, 2A6, 2B6, 2C19, and 2D6 (IC(50) > or = 250 microM) was found; a moderate inhibition was observed for CYP1A2 and 2C8. The most prominent inhibition effect was found with CYP3A4 and CYP2C9 (IC(50) < or = 50 microM). Using mass spectometry detection, production of O-demethylated (the main metabolite) as well as hydroxylated derivatives of silybin formed by P450 enzymes was detected. The effect of different P450 inhibitors on the formation of O-demethylated product was also studied. In particular, a relatively specific inhibitor of CYP2C8 (quercetin) markedly inhibited the formation of this metabolite. With the help of recombinant enzymes (bactosomes), it was confirmed that the CYP2C8 enzyme is responsible for the reaction leading to O-demethylated silybin.
650    _2
$a antioxidancia $x farmakologie $x metabolismus $7 D000975
650    _2
$a aromatické hydroxylasy $x antagonisté a inhibitory $x genetika $x metabolismus $7 D001189
650    _2
$a oxid uhelnatý $x farmakologie $7 D002248
650    _2
$a katalýza $x účinky léků $7 D002384
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a cytochrom P-450 CYP1A2 $x genetika $x metabolismus $7 D019388
650    _2
$a cytochrom P-450 CYP3A $7 D051544
650    _2
$a systém (enzymů) cytochromů P-450 $x genetika $x metabolismus $7 D003577
650    _2
$a inhibitory enzymů $x farmakologie $x metabolismus $7 D004791
650    _2
$a Escherichia coli $x genetika $x metabolismus $7 D004926
650    _2
$a lidé $7 D006801
650    _2
$a jaterní mikrozomy $x enzymologie $x metabolismus $x účinky léků $7 D008862
650    _2
$a molekulární struktura $7 D015394
650    _2
$a quercetin $x farmakologie $7 D011794
650    _2
$a rekombinantní proteiny $x metabolismus $7 D011994
650    _2
$a silymarin $x farmakologie $x chemie $x metabolismus $7 D012838
650    _2
$a financování organizované $7 D005381
650    _2
$a inhibitory cytochromu P450 CYP1A2 $7 D065609
650    _2
$a inhibitory cytochromu P450 $7 D065607
700    1_
$a Anzenbacherová, Eva, $d 1959- $7 stk2008428613
700    1_
$a Papoušková, Barbora $7 xx0137487
700    1_
$a Lemr, Karel, $d 1963- $7 ola2002157903
700    1_
$a Lužná, Pavla, $d 1983- $7 xx0165786
700    1_
$a Veinlichová, A. $7 _AN051220
700    1_
$a Anzenbacher, Pavel, $d 1947- $7 xx0034447
700    1_
$a Šimánek, Vilím, $d 1942- $7 ola200208149
773    0_
$w MED00001446 $t Drug metabolism and disposition $g Roč. 35, č. 11 (2007), s. 2035-2039 $x 0090-9556
910    __
$a ABA008 $b x $y 7
990    __
$a 20101103092445 $b ABA008
991    __
$a 20101103134245 $b ABA008
999    __
$a ok $b bmc $g 801912 $s 666672
BAS    __
$a 3
BMC    __
$a 2007 $b 35 $c 11 $d 2035-2039 $i 0090-9556 $m Drug metabolism and disposition $n Drug Metab Dispos $x MED00001446
LZP    __
$a 2010-B3/vtme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...